美国 · SEC FORM 4
Intellia Therapeutics, Inc.
NTLA · Nasdaq · CIK 0001652130 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
13 同一窗口内观察到的 Form 4 交易行
6 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-01-05 · Cohen Fred E.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 45,110,513
- 上期报告
- 46,681,609
- 日均成交量
- 4,765,594
- 回补天数
- 9.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
35 transaction lines in the latest 365-day window; 441 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | 卖出 (S) | Common Stock | 1,864 | USD 12.43 | USD 23,170 | SEC 申报 ↗ |
| 2026-08-21 | LEONARD JOHN M | 卖出 (S) | Common Stock | 2,785 | USD 13.00 | USD 36,205 | SEC 申报 ↗ |
| 2026-08-20 | LEONARD JOHN M | 卖出 (S) | Common Stock | 19,890 | USD 12.60 | USD 250,614 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | 卖出 (S) | Common Stock | 1,864 | USD 12.43 | USD 23,170 | SEC 申报 ↗ |
| 2026-08-21 | LEONARD JOHN M | 卖出 (S) | Common Stock | 2,785 | USD 13.00 | USD 36,205 | SEC 申报 ↗ |
| 2026-08-20 | LEONARD JOHN M | 卖出 (S) | Common Stock | 19,890 | USD 12.60 | USD 250,614 | SEC 申报 ↗ |
| 2026-07-22 | Dulac Edward J III | 卖出 (S) | Common Stock | 8,111 | USD 11.25 | USD 91,249 | SEC 申报 ↗ |
| 2026-07-02 | Dulac Edward J III | 卖出 (S) | Common Stock | 4,677 | USD 18.00 | USD 84,186 | SEC 申报 ↗ |
| 2026-07-01 | Dube Michael P | 卖出 (S) | Common Stock | 2,641 | USD 16.78 | USD 44,316 | SEC 申报 ↗ |
| 2026-06-09 | Verwiel Frank | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Keresty Georgia | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Goff Brian | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | GOODMAN JESSE | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Cohen Fred E | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | CHASE WILLIAM J | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Bhanji Muna | 奖励／授予 (A) | Common Stock | 9,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Clark Eliana | 卖出 (S) | Common Stock | 607 | USD 13.78 | USD 8,364 | SEC 申报 ↗ |
| 2026-03-02 | BASTA JAMES | 卖出 (S) | Common Stock | 1,211 | USD 13.78 | USD 16,688 | SEC 申报 ↗ |
| 2026-03-01 | Schultes Birgit C | 奖励／授予 (A) | Common Stock | 39,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Lebwohl David | 奖励／授予 (A) | Common Stock | 9,943 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | LEONARD JOHN M | 奖励／授予 (A) | Common Stock | 156,400 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Dulac Edward J III | 奖励／授予 (A) | Common Stock | 61,280 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Dube Michael P | 奖励／授予 (A) | Common Stock | 17,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | Clark Eliana | 奖励／授予 (A) | Common Stock | 7,353 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-01 | BASTA JAMES | 奖励／授予 (A) | Common Stock | 46,080 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-05 | Schultes Birgit C | 卖出 (S) | Common Stock | 8,508 | USD 9.21 | USD 78,359 | SEC 申报 ↗ |
| 2026-01-05 | Lebwohl David | 卖出 (S) | Common Stock | 11,903 | USD 9.21 | USD 109,627 | SEC 申报 ↗ |
| 2026-01-05 | LEONARD JOHN M | 卖出 (S) | Common Stock | 34,146 | USD 9.21 | USD 314,485 | SEC 申报 ↗ |
| 2026-01-05 | Dulac Edward J III | 卖出 (S) | Common Stock | 6,379 | USD 9.21 | USD 58,751 | SEC 申报 ↗ |
| 2026-01-05 | Dube Michael P | 卖出 (S) | Common Stock | 2,989 | USD 9.21 | USD 27,529 | SEC 申报 ↗ |
| 2026-01-05 | Cohen Fred E | 买入 (P) | Common Stock | 150,000 | USD 9.35 | USD 1,402,500 | SEC 申报 ↗ |
| 2026-01-05 | Clark Eliana | 卖出 (S) | Common Stock | 9,515 | USD 9.21 | USD 87,633 | SEC 申报 ↗ |
| 2026-01-05 | BASTA JAMES | 卖出 (S) | Common Stock | 10,397 | USD 9.21 | USD 95,756 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NTLA |
| CIK | 0001652130 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2835 In Vitro & In Vivo Diagnostic Substances |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 441 transaction lines from 2020-05-26 to 2026-10-02 2 P purchase lines · 260 S sale lines · 179 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.